MannKind (MNKD) is in focus after the U.S. Food and Drug Administration approved Furoscix ReadyFlow, an at-home autoinjector ...

MannKind (NASDAQ:MNKD) said the U.S. Food and Drug Administration approved Furoscix ReadyFlow, an auto-injector designed to ...

MannKind stock has declined 26.2% year to date, yet valuation checks suggest it may now be trading below an estimated ...

Performance-based RSUs vested at 83% of target, reflecting MannKind's stock performance against industry benchmarks. Singh ...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA ...

MannKind Corporation announced today that it plans to meet with the FDA to discuss a potential supplemental new drug application (sNDA) for its inhaled insulin product, Afrezza, following positive six ...

Mannkind Corporation MNKD shares are trading higher as the company recently announced the U.S. Food and Drug Administration’s ...

MannKind recently received U.S. FDA approval for Afrezza Inhalation Powder for children and adolescents aged 6 and older with type 1 or type 2 diabetes, making it the first needle-free mealtime ...

Good afternoon, and welcome to the MannKind Corporation conference call to discuss the U.S. FDA approval of Afrezza in pediatrics. As a reminder, this call is being recorded on May 29, 2026, and will ...

Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload July 24, 2026 9:00 ...

The transaction was a non-discretionary execution conducted to satisfy tax withholding obligations linked to the performance-based vesting of restricted stock units. Following the sale, the Chief ...